Design, Synthesis, and In Vitro Evaluation of Carbamate Derivatives of

5868

J. Med. Chem. 2007, 50, 5868

Additions and Corrections

2007, Volume 50

Mikko J. Myllyma1 ki, Susanna M. Saario, Antti O. Kataja, Joel A. Castillo-Melendez, Tapio Nevalainen, Risto O. Juvonen, Tomi Ja1 rvinen, and Ari M. P. Koskinen*: Design, Synthesis, and In Vitro Evaluation of Carbamate Derivatives of 2-Benzoxazolyl- and 2-Benzothiazolyl-(3hydroxyphenyl)-methanones as Novel Fatty Acid Amide Hydrolase Inhibitors. Page 4238. In Table 1 in the row for compound 23, the reference number in the 11th column labeled “IC50 (95% CI)a FAH” should be “30” instead of “25” and the reference number in the 12th column labeled “MAGL” should be “15” instead of “11”. In the row for compound 24 and in the 11th column labeled “IC50 (95% CI)a FAH”, the reference number should be “29” instead of “24” and the Ki value should be “2.3 nM” instead of “0.23 nM”. JM701230U 10.1021/jm701230u Published on Web 10/18/2007

2005, Volume 48

Michael J. Costanzo,* Harold R. Almond, Jr., Leonard R. Hecker, Mary R. Schott, Stephen C. Yabut, Han-Cheng Zhang, Patricia Andrade-Gordon, Thomas W. Corcoran, Edward C. Giardino, Jack A. Kauffman, Joan M. Lewis, Lawrence de Garavilla, Barbara J. Haertlein, and Bruce E. Maryanoff*: In-Depth Study of Tripeptide-Based R-Ketoheterocycles as Inhibitors of Thrombin. Effective Utilization of the S1′ Subsite and Its Implications to Structure-Based Drug Design. Page 1992. Structures 41 and 42 in Scheme 4 should have a CH2 group inserted between the cyclohexane ring and the NH2 group. Page 2005. In ref 3a, the term “Asp-104” is incorrect and should be replaced by “Asp-102”. JM701211Q 10.1021/jm701211q Published on Web 10/12/2007